Ligand Pharmaceuticals Incorporated
LGNDNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $6.52B
- P/E (TTM)
- 33.05
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $175.89$326.63
- Volume (live)
- -
- Avg. volume (3M)
- 253.54K
Ligand Pharmaceuticals Incorporated (LGND) Stock Price & Financial Analysis
Ligand Pharmaceuticals Incorporated Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $292.56 - $297.67 |
|---|---|
| 52-Week High | $326.63 |
| 52-Week Low | $175.89 |
| Open | $297.67 |
| Volume (last close) | 164.50K |
| Average Volume (3M) | 253.54K |
| Revenue (TTM) | 290.54M |
|---|---|
| Net Income (TTM) | 197.22M |
| Free Cash Flow (TTM) | 122.97M |
| EPS (TTM) | $9.50 |
| Profit Margin | 67.88% |
| Operating Margin | 34.74% |
| Return on Equity (ROE) | 20.38% |
| Debt to Equity | 1.17 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Last Dividend Ex-Date | Jul 2, 2010 |
| Market Cap | 6.52B |
|---|---|
| Shares Outstanding | 21.84M |
| P/E Ratio (TTM) | 33.05 |
| Price to Sales (P/S) | 22.44 |
| Price to Book (P/B) | 6.74 |
| EV/EBITDA | 24.27 |
| 50-Day MA | $292.63 |
|---|---|
| 200-Day MA | $245.90 |
| 1-Year Change | +64.33% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Ligand Pharmaceuticals Incorporated at a Glance
As of the Oct 16, 2026 close, Ligand Pharmaceuticals Incorporated (LGND) has a market capitalization of $6.52B. The stock trades at 33.0× trailing earnings and 22.4× sales. Over the trailing twelve months it earned $197.22M on revenue of $290.54M (a 67.9% profit margin) and generated $122.97M of free cash flow. Revenue grew 54.9% year over year.
As of its latest reported balance sheet, it holds $1.01B in cash and securities against $1.13B of debt, a net debt position of $124.75M.
Ligand Pharmaceuticals Incorporated does not currently pay a dividend.
The share price is up 64.3% over the past year. At $295.54 (the Oct 16, 2026 close) it sits within its 52-week range of $175.89 to $326.63, above its 200-day moving average of $245.90.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $359.83, 21.8% above the Oct 16, 2026 close.
Frequently Asked Questions About Ligand Pharmaceuticals Incorporated
What is the current stock price for LGND?
As of the Oct 16, 2026 close, LGND stock trades at $295.54. The 52-week range is $175.89–$326.63, with a day range of $292.56–$297.67.
What is the P/E ratio for LGND?
As of the Oct 16, 2026 close, Ligand Pharmaceuticals Incorporated's trailing twelve-month (TTM) P/E ratio is 33.0, meaning investors pay $33.0 for every $1 of annual earnings. Ligand Pharmaceuticals Incorporated operates in the Healthcare sector.
Does LGND pay dividends?
Ligand Pharmaceuticals Incorporated does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for LGND?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for LGND is Buy. The average 12-month price target is $359.83, a 21.8% upside from the Oct 16, 2026 close of $295.54.
What is the market cap of LGND?
As of the Oct 16, 2026 close, Ligand Pharmaceuticals Incorporated's market capitalization is $6.45B, classifying it as a mid-cap company. Ligand Pharmaceuticals Incorporated operates in the Healthcare sector within the Biotechnology industry.